The FDA has approved a subcutaneous formulation of ocrelizumab for the treatment of relapsing and primary progressive multiple sclerosis. This new injection can be administered in 10 minutes by a healthcare professional and is the first twice-a-year injection approved for both types of MS. The approval was based on data from a phase 3 trial showing no significant difference in blood levels compared to the intravenous formulation. The safety profile was similar, with injection site reactions being the most common adverse event. This new formulation may provide greater flexibility for healthcare providers and patients with MS.
Source link
FDA Okays Subcutaneous Ocrelizumab for MS
